By Stephanie Nebehay
Geneva - Bird flu patients should receive Tamiflu as a frontline treatment, but doctors may also consider combining it with an older class of effective flu drugs, the World Health Organisation (WHO) said on Friday.
The option of so-called "dual antiviral therapy" was among the latest clinical recommendations issued by the United Nations agency for countries battling outbreaks of the deadly H5N1 virus among humans.
The recommendations were drawn up at a closed-door meeting of 30 international experts in late March, hosted by the WHO, which published them on its website on Friday.
'Dual antiviral therapy' It said the experts strongly recommended Tamiflu, a flu drug made by Swiss-based Roche, be used. Zanamivir - which is marketed as Relenza by GlaxoSmithKline - was a second choice. Relenza is available only for inhalation.
Continues Below ↓
Both drugs belong to a new class called neuraminidase inhibitors and can prevent the virus from infecting cells in the first place.
But the experts said amantadine and rimantadine - in an older class of drugs known as M2 inhibitors which are cheaper - may be used alongside the newer drugs in certain cases.
"Clinicians might administer a combination of a neuraminidase inhibitor and an M2 inhibitor if local surveillance data show that the H5N1 virus is known or likely to be susceptible," the WHO report said.
Nahoko Shindo, a WHO medical officer who took part in the experts' meeting, said the dual therapy could block the virus from replicating in two different ways. "This is the first time we clearly state the possibility of dual therapy to be considered in case you are facing a H5N1 outbreak," Shindo, who advised hospitals in eastern Turkey during the country's outbreak last January, told Reuters.
"Even if you are in the middle of an outbreak, dual therapy can do good.
Continues...
|
StumbleUpon
Reddit
Digg
Delicious
Newsvine
Facebook
muti
Twitter
